Synopsis
Synopsis
0
USDMF
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Floxacillin
2. Fluorochloroxacillin
1. Floxacillin
2. 5250-39-5
3. Floxapen
4. Flucloxacilina
5. Flucloxacilline
6. Flucloxacillinum
7. Floxacillin [usan]
8. Flucloxacillin Sodium
9. Flucloxacilina [inn-spanish]
10. Flucloxacilline [inn-french]
11. Flucloxacillinum [inn-latin]
12. Brl 2039
13. 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin
14. Flucloxacillin-sodium
15. Chebi:5098
16. Floxacillin (usan)
17. Flucloxacillin (inn)
18. Flucloxacillin [inn]
19. Brl-2039
20. Floxapen (tn)
21. (2s,5r,6r)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
22. 43b2m34g2v
23. (2s,5r,6r)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
24. 6-(3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid
25. Floxacillin Sodium Anhydrous
26. Flucloxacillin Sodium Anhydrous
27. 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid,6-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-,(2s,5r,6r)-
28. Mfipc
29. Nsc-277175
30. Einecs 226-051-0
31. Unii-43b2m34g2v
32. Flucloxacillin,(s)
33. Floxacillin [mi]
34. Epitope Id:117416
35. Schembl3823
36. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2s(2alpha,5alpha,6beta))
37. Flucloxacillin [mart.]
38. Chembl222645
39. Flucloxacillin [who-dd]
40. Dtxsid8023056
41. Gtpl10910
42. Brl2039
43. Hy-a0246
44. Zinc4102187
45. Bdbm50370590
46. Db00301
47. Ncgc00485420-01
48. (2s,5r,6r)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
49. (2s,5r,6r)-6-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-amido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
50. 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido]-2,2-dimethylpenam-3alpha-carboxylic Acid
51. Nci60_002254
52. Cs-0017591
53. D04196
54. 250f395
55. Q1994556
56. W-105817
57. Brd-k27871792-001-01-8
58. Flucloxacillin, Antibiotic For Culture Media Use Only
59. (2s,5r,6r)-6-(3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
60. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 6-(((3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2s(2.alpha.,5.alpha.,6.beta.))
| Molecular Weight | 453.9 g/mol |
|---|---|
| Molecular Formula | C19H17ClFN3O5S |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 453.0561477 g/mol |
| Monoisotopic Mass | 453.0561477 g/mol |
| Topological Polar Surface Area | 138 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 758 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used to treat bacterial infection by susceptible microorganisms.
Flucloxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Flucloxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Flucloxacillin results from the inhibition of cell wall synthesis and is mediated through flucloxacillin binding to penicillin binding proteins (PBPs). Flucloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01CF05
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01C - Beta-lactam antibacterials, penicillins
J01CF - Beta-lactamase resistant penicillins
J01CF05 - Flucloxacillin
Absorption
Bioavailability is 5070% following oral administration.
Hepatic.
Flucloxacillin has known human metabolites that include 6-[[3-(2-Chloro-6-fluorophenyl)-5-(hydroxymethyl)-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
0.751 hour
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, flucloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that flucloxacillin interferes with an autolysin inhibitor.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
49
PharmaCompass offers a list of Floxacillin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Floxacillin manufacturer or Floxacillin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Floxacillin manufacturer or Floxacillin supplier.
PharmaCompass also assists you with knowing the Floxacillin API Price utilized in the formulation of products. Floxacillin API Price is not always fixed or binding as the Floxacillin Price is obtained through a variety of data sources. The Floxacillin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Flucloxacilina [INN-Spanish] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flucloxacilina [INN-Spanish], including repackagers and relabelers. The FDA regulates Flucloxacilina [INN-Spanish] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flucloxacilina [INN-Spanish] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Flucloxacilina [INN-Spanish] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Flucloxacilina [INN-Spanish] supplier is an individual or a company that provides Flucloxacilina [INN-Spanish] active pharmaceutical ingredient (API) or Flucloxacilina [INN-Spanish] finished formulations upon request. The Flucloxacilina [INN-Spanish] suppliers may include Flucloxacilina [INN-Spanish] API manufacturers, exporters, distributors and traders.
click here to find a list of Flucloxacilina [INN-Spanish] suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Flucloxacilina [INN-Spanish] CEP of the European Pharmacopoeia monograph is often referred to as a Flucloxacilina [INN-Spanish] Certificate of Suitability (COS). The purpose of a Flucloxacilina [INN-Spanish] CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Flucloxacilina [INN-Spanish] EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Flucloxacilina [INN-Spanish] to their clients by showing that a Flucloxacilina [INN-Spanish] CEP has been issued for it. The manufacturer submits a Flucloxacilina [INN-Spanish] CEP (COS) as part of the market authorization procedure, and it takes on the role of a Flucloxacilina [INN-Spanish] CEP holder for the record. Additionally, the data presented in the Flucloxacilina [INN-Spanish] CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Flucloxacilina [INN-Spanish] DMF.
A Flucloxacilina [INN-Spanish] CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Flucloxacilina [INN-Spanish] CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Flucloxacilina [INN-Spanish] suppliers with CEP (COS) on PharmaCompass.
A Flucloxacilina [INN-Spanish] written confirmation (Flucloxacilina [INN-Spanish] WC) is an official document issued by a regulatory agency to a Flucloxacilina [INN-Spanish] manufacturer, verifying that the manufacturing facility of a Flucloxacilina [INN-Spanish] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Flucloxacilina [INN-Spanish] APIs or Flucloxacilina [INN-Spanish] finished pharmaceutical products to another nation, regulatory agencies frequently require a Flucloxacilina [INN-Spanish] WC (written confirmation) as part of the regulatory process.
click here to find a list of Flucloxacilina [INN-Spanish] suppliers with Written Confirmation (WC) on PharmaCompass.
Flucloxacilina [INN-Spanish] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Flucloxacilina [INN-Spanish] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flucloxacilina [INN-Spanish] GMP manufacturer or Flucloxacilina [INN-Spanish] GMP API supplier for your needs.
A Flucloxacilina [INN-Spanish] CoA (Certificate of Analysis) is a formal document that attests to Flucloxacilina [INN-Spanish]'s compliance with Flucloxacilina [INN-Spanish] specifications and serves as a tool for batch-level quality control.
Flucloxacilina [INN-Spanish] CoA mostly includes findings from lab analyses of a specific batch. For each Flucloxacilina [INN-Spanish] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Flucloxacilina [INN-Spanish] may be tested according to a variety of international standards, such as European Pharmacopoeia (Flucloxacilina [INN-Spanish] EP), Flucloxacilina [INN-Spanish] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flucloxacilina [INN-Spanish] USP).
